Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials

Efficacy and tolerability of therapies set under pharmacogenetic tools suggestions: A systematic review with meta-analysis about mood disorders

(2022) Marta Ielmini et al.   PSYCHIATRY RESEARCH

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial

(2022) Arun K. Tiwari et al.   Translational Psychiatry

Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder

(2022) David W. Oslin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews

(2021) Melissa L. Rethlefsen et al.   Systematic Reviews

Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial

(2021) John Papastergiou et al.   CTS-Clinical and Translational Science

A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression

(2021) Michael J McCarthy et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Randomized, controlled, participant‐ and rater‐blind trial of pharmacogenomic test‐guided treatment versus treatment as usual for major depressive disorder

(2020) Roy H. Perlis et al.   DEPRESSION AND ANXIETY

Pharmacogenomic testing and antidepressant response: problems and promises

(2020) Tawny L. Smith et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial

(2020) Changsu Han et al.   Clinical Psychopharmacology and Neuroscience

Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study

(2019) John F. Greden et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Pharmacogenetics and Depression: A Critical Perspective

(2019) Filippo Corponi et al.   Psychiatry Investigation

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study

(2019) Xiaoxiao Shan et al.   Frontiers in Neuroscience

Short-term and long-term measures of cortisol in saliva and hair in atypical and non-atypical depression

(2018) A. Herane-Vives et al.   ACTA PSYCHIATRICA SCANDINAVICA

Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility

(2018) Paul Bradley et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Role of Kynurenine Pathway and its Metabolites in Mood Disorders: A Systematic Review and Meta-Analysis of Clinical Studies

(2018) Danilo Arnone et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis

(2018) Joshua D. Rosenblat et al.   JOURNAL OF AFFECTIVE DISORDERS

Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials

(2018) Chad A Bousman et al.   PHARMACOGENOMICS

Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?

(2018) Haley V. Solomon et al.   PSYCHIATRY RESEARCH

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial

(2018) Changsu Han et al.   Clinical Psychopharmacology and Neuroscience

Resting-state brain alteration after a single dose of SSRI administration predicts 8-week remission of patients with major depressive disorder

(2016) Y. Cheng et al.   PSYCHOLOGICAL MEDICINE

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6andCYP2C19Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

(2015) JK Hicks et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Inflammation and clinical response to treatment in depression: A meta-analysis

(2015) R. Strawbridge et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

(2015) Anthony Cleare et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report

(2015) Ajeet B. Singh   Clinical Psychopharmacology and Neuroscience

Applications of CYP450 Testing in the Clinical Setting

(2013) C. F. Samer et al.   Molecular Diagnosis & Therapy

Consistency of drug–drug and gene–drug interaction information in US FDA-approved drug labels

(2013) Daniela J Conrado et al.   PHARMACOGENOMICS

Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature

(2012) A. J. Ferrari et al.   PSYCHOLOGICAL MEDICINE

Magnetic resonance imaging studies in unipolar depression: Systematic review and meta-regression analyses

(2011) D. Arnone et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis

(2009) D. Arnone et al.   BRITISH JOURNAL OF PSYCHIATRY